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Abstract
Background: This study examined the development of chronic pain, a cardinal symptom of rheumatoid arthritis
(RA), in mice with antigen- and collagen-induced arthritis (ACIA). Since the role of CD8+ T cells in arthritis is
controversial, we investigated the consequences of CD8-depletion on arthritis development and opioid modulation
of pain in this novel model of chronic autoimmune arthritis.
Methods: Disease severity in control and CD8-depleted animals was determined by histological assessment of
knee-joint sections and measurement of autoantibody formation. Pain was evaluated by measuring mechanical
allodynia and thermal hyperalgesia in von Frey and Hargreaves tests, respectively. The production and release of
endogenous opioids and inflammatory cytokines was assessed in immunoassays.
Results: In ACIA, mice display persistent mechanical allodynia and thermal hyperalgesia for more than 2 months
after induction of arthritis. The blockade of peripheral opioid receptors with naloxone-methiodide (NLXM)
transiently increased thermal hyperalgesia, indicating that endogenous opioid peptides were released in the
arthritic joint to inhibit pain. CD8+ T cell depletion did not affect autoantibody formation or severity of joint
inflammation, but serum levels of the pro-inflammatory cytokines TNFα and IL-17 were increased. The release of
opioid peptides from explanted arthritic knee cells and the NLXM effect were significantly reduced in the absence
of CD8+ T cells.
Conclusions: We have successfully modeled the development of chronic pain, a hallmark of RA, in ACIA.
Furthermore, we detected a yet unknown protective role of CD8+ T cells in chronic ACIA since pro-inflammatory
cytokines rose and opioid peptide release decreased in the absence of these cells.
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Background
Chronic disorders with an inflammatory component are
the most common diseases of aging and represent our
greatest health threat [1]. Such disorders include rheuma-
toid arthritis (RA), a debilitating condition with significantly
reduced quality of life characterized by severe pain, auto-
immune responses, and joint inflammation [2]. Significant
progress has been made regarding anti-inflammatory ther-
apies, especially in the field of monoclonal antibodies
against several proinflammatory cytokines such as IL-6,
TNFα, and IL-1 [3–5].
However, chronic pain is still an unresolved clinical
problem [6]. Standard analgesic treatments such as
nonsteroidal anti-inflammatory drugs, opioids, or ste-
roids exhibit detrimental side effects including sedation,
respiratory depression, and an enhanced risk for gastro-
intestinal ulcers, bleeding, myocardial infarction, stroke,
and infections [7, 8]. Thus, there is an urgent need for
a better understanding of chronic pain conditions in
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adequate animal models to provide insights into cellu-
lar and molecular mechanisms of ongoing ache.
Antigen- and collagen-induced arthritis (ACIA) is a
new mouse model that displays key features of RA such as
chronic joint inflammation, cartilage and bone erosion,
and prominent autoimmune responses against autologous
collagen II, and anti-citrullinated peptide/protein anti-
bodies (ACPA) that can be observed in the majority
of RA patients [9]. ACPA are early markers for RA
that can be detected years before disease onset [10,
11] and are associated with more severe joint
destruction [12, 13]. With regard to immune cells,
particularly CD8+ cytotoxic T cells (CTLs) have
been shown to contribute to tissue destruction in
autoimmune diseases. Given these similarities to the
human disease, we set out to investigate if ACIA
also resulted in a “chronic pain” phenotype and to
identify cell types and molecules that play a role in
pain sensing.
The immune system is linked to the nervous system
by pro-inflammatory cytokines that directly or indir-
ectly enhance the sensitivity of inflamed tissue towards
painful stimuli (hyperalgesia) [14, 15]. In addition, im-
mune cells produce anti-inflammatory cytokines and
can potently reduce pain by the liberation of opioid
peptides such as enkephalins, endorphins, and dynor-
phin [16–18]. Such mechanisms have been predomin-
antly investigated in acute inflammatory injuries of
animals and humans, but their relevance in chronic
inflammation is not yet well understood. Murine colitis
models of T cell-induced and DSS-induced colitis start
shedding light on the regulation of pain by T lympho-
cytes [19, 20].
It is widely assumed that some T cell subpopulations
play a pro-nociceptive role. However, several studies
indicate that T cell deficiency increases the sensitivity
towards painful stimuli in rodent models of acute visceral
[21], inflammatory [22, 23], and neuropathic pain [24].
This raises the question if lymphocytes and, more
specifically CD8+ CTLs, exert opioid-mediated antinoci-
ception under chronic inflammatory conditions. This led
us to investigate the “pain” profile and opioid-mediated
anti-nociception in ACIA in relation to histological
parameters and to CTL depletion.
Methods
Mice
Female BALB/c mice were purchased from Charles River
(Sulzfeld, Germany) and Janvier (France). Mice were
used at 10–14-weeks of age. All animal studies were
approved by the state ethics committee (Landesamt für
Gesundheit und Soziales, Berlin, Germany) and per-
formed according to institutional and state guidelines,
under specific pathogen-free conditions.
ACIA model
BALB/c mice were immunized by subcutaneous (s.c.) in-
jection of 100 μg methylated bovine serum albumin
(mBSA, Sigma-Aldrich, Schnelldorf, Germany) in 50 μl
PBS emulsified with 50 μl complete Freund’s adjuvant
(CFA, Sigma-Aldrich), followed 1 week later by a second
s.c. immunization with mBSA plus bovine type II colla-
gen in incomplete CFA [9]. One week later, mice were
immunized s.c. with 50 μg mBSA and 100 μg bovine
collagen type II (mdbioproducts, Zurich, Switzerland) in
50 μl PBS emulsified with 50 μl Freund’s incomplete
adjuvant (IFA, Sigma-Aldrich). In parallel to each
immunization step, 200 ng of Bordetella pertussis
toxin (PTx, Calbiochem, La Jolla, CA, USA) were
injected intraperitoneally (i.p.). Fourteen days later,
on day 0, arthritis was induced by intraarticular (i.a.)
injection of 50 μg mBSA dissolved in 20 μl PBS into
one knee joint (ipsilateral) during brief isoflurane
(Abbot, Wiesbaden-Delkenheim, Germany) anesthesia.
The same volume of the vehicle (PBS) was injected into
the contralateral knee. An “induction-only” control group
of animals were not immunized with s.c. mBSA, but in-
stead received s.c. PBS emulsified with adjuvant. On day 0,
mBSA was injected into the ipsilateral and PBS into the
contralateral knee joint.
Depletion of cytotoxic T cells
To deplete cytotoxic T cells (CTL), ACIA mice received
i.p. injections of 90 μg anti-CD8 [25] (Leinco Technolo-
gies, Inc., St. Louis, MO, USA), diluted in 200 μl sterile
saline. The antibody was injected every 9–10 days start-
ing 3 days before i.a. mBSA injection. Control animals
received the isotype-matched control antibody (Leinco
Technologies, Inc.). The amount of antibody was titrated
so that depletion would last until the end of the study
period (i.e., 60 days after arthritis induction).
Immunohistochemical analysis
Animals were sacrificed and both knee joints were fixed
in 4% buffered formaldehyde, decalcified with EDTA,
and embedded in paraffin. Serial sections (4–5 μm thick)
were cut and stained with hematoxylin and eosin (H&E)
for microscopic evaluation. Scoring of the knee sections
was performed in a blinded manner in three to four
sections per knee joint. Two different scores were used,
one for the severity of inflammation and one for the
Treatment ACIA Induction-only control
s.c. immunization, day -21 mBSA + CFA PBS + CFA
s.c. immunization, day -14 mBSA + IFA PBS + IFA
i.a. ipsilateral knee, day 0 mBSA mBSA
i.a. contralateral knee, day 0 PBS PBS
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degree of destruction. Inflammation was scored by the
degree of synovial hyperplasia (0–3 points), the amount
of mononuclear cells infiltrating the synovial membrane
(0–3 points), and fibrosis (0–3 points). Destruction of
the joint was scored according to the level of cartilage
and bone destruction (0–3 points) and pannus formation
(0–3 points). Zero points in any of the categories corre-
sponded to the absence of the parameter, 3 points indi-
cated the strongest pathological phenotype, and points
for each parameter were added up to the overall score.
The experimenter was not aware of the preceding treat-
ment of the animals.
Assessment of nociceptive behavior
von Frey test Mechanical hypersensitivity “allodynia”
was assessed by applying von Frey filaments (Stoelting
Co., Wood Dale, IL) as previously reported [26]. Briefly,
animals were habituated to the test cages daily starting
6 days prior to behavioral testing. Mechanical allodynia
was evaluated with calibrated von Frey filaments applied
to the plantar surface of the hind paws using an up-down
method [27]. The following calibrated von Frey filaments
were used: 0.078 mN (0.0056 g), 0.196 mN (0.0076 g),
0.392 mN (0.041 g), 0.686 mN (0.059 g), 1.569 mN
(0.14 g), 3.922 mN (0.28 g), 5.882 mN (0.54 g), 9.804 mN
(0.66 g), 13.725 mN (1.15 g), 19.608 mN (2.35 g), and
39.216 mN (4.37 g) (Stoelting, Wood Dale, IL). The
filaments were applied to the plantar surface of the hind
paws for about 3 s until they bowed. The up-down
method [28] was used to estimate 50% withdrawal thresh-
olds. Testing began using a 3.922-mN (0.28 g) filament. If
the animal withdrew the paw, the just-preceding weaker
filament was applied. In the case of no withdrawal, the
next stronger filament was applied. The maximal number
of applications was six to nine, and the cut-off was
39.216 mN (4.37 g). Uninjured paws were typically with-
drawn at the next filament (58.82 mN or 5.3 g), according
to our previous studies [26].
Hargreaves test The latency required to elicit paw with-
drawal in response to radiant heat applied to the plantar
surface of a hind paw from underneath a glass floor with a
high intensity light bulb was measured with an electronic
timer (IITC Inc. Life Science, Woodland Hills, CA). The
stimulus intensity was adjusted to yield a baseline paw
withdrawal latency of 10–12 s in healthy animals. The
average of two measurements per paw assessed within a
1-min interval was calculated in seconds. To avoid tissue
damage, a cut-off of 20 s was employed.
Behavioral protocols Animals were habituated to the
test cages daily starting 6 days prior to behavioral testing
and were randomly assigned to the different treatment
groups. Treatment assignments and preparation of syrin-
ges were performed by another person to assure experi-
ment was performed in a blinded manner. Baseline
mechanical and thermal thresholds were assessed once
before each immunization step. The animals were tested
daily during the acute phase (2–7 days after i.a. injec-
tions), followed by weekly testing until the end of the
observation period (day 64).
Local endogenous opioid-mediated pain control was
evaluated by injecting i.a. naloxone-methiodide (NLXM)
(1 μg/10 μl) under isoflurane anesthesia. Control mice
received solvent. The effect on heat sensitivity was
assessed at 15 and 30 min after drug application using
the Hargreaves test.
Immunoglobulin production and ELISA
For the analysis of serum components, mice were bled
retro-orbitally at regular intervals. Analysis of antigen-
specific IgG titers or cytokine levels in the serum was per-
formed with capture ELISA. To measure mBSA-specific
IgG, immunostep microtiter plates (Nunc, Langenselbold,
Germany) were coated with 2 μg per well mBSA in PBS
and washed and incubated with diluted serum. Bound
serum antibodies were detected using horseradish
peroxidase-conjugated rabbit anti-mouse serum (South-
ern Biotech, Eeling, Germany). For the detection of
ACPA, the anti-MCV (mutated citrullinatedvimentin)
ELISA (OrgentecDiagnostica, Mainz, Germany) was used.
Serum TNFα level was determined with the mouse TNFα
DuoSet ELISA (R&D systems). To detect the IL-17A
level in the serum, the purified TC11-18H10.1 anti-
body (BioLegend) served as capture antibody, in con-
junction with the biotinylated TC11-8H4 (BioLegend)
as detection antibody and recombinant murine inter-
leukin 17 (IL-17) (BioLegend).
Detection of opioid peptides
Ipsilateral knee joints from CTL-depleted and isotype-
treated arthritic mice were dissected in the late chronic
phase, i.e., >day 60. Knee joints were cut in half and sub-
jected to enzyme digestion using RMPI-1640 medium
supplemented with 3 mg/ml hyaluronidase and 1 mg/ml
collagenase II (both Sigma-Aldrich) for 30 min at room
temperature. The knee joint was grinded, and tissue
homogenates were filtered twice using 70- and 40-μm
cell strainers, respectively. Cell suspensions were washed
in pure RMPI medium, spun down for 10 min at ×350g,
and resuspended in 250 μl of pure medium. Cells were
kept for 1.5 h at 37 °C under agitation; the supernatants
were harvested after spinning and kept at −80 °C. The
amounts of liberated opioid peptides were determined
using a Methionine-enkephalin radioimmunoassay (RIA,
Bachem, Peninsula Laboratories, USA) and a fluorescent
human/rat beta-endorphin enzyme immunoassay (EIA,
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Phoenix Peptides) as previously described [29]. The
EIA kit is validated by the manufacturer to be 100%
cross reactive for murine endorphin. For RIA, 100 μl
of supernatants were analyzed in duplicates. The
remaining supernatants were analyzed in duplicate
using EIA. Both assays are suitable to detect opioid
peptides at the pg-level.
Statistical analysis
All data were documented using Microsoft Excel 2003
for Windows (Microsoft Corporation). GraphPad Prism
Version 5.01 for Windows (GraphPad Software, Inc.)
software was used for statistical analyses. Data were ana-
lyzed for equal variance and for normal distribution
using the D’Agostino & Pearson omnibus normality test
or Kolmogorov-Smirnov test. Normally distributed inde-
pendent data were analyzed by the Student t test and
nonparametric independent data by the Mann-Whitney
U test if only two groups were compared. To compare
two groups of normally distributed dependent data, the
paired t test was used. In case of nonparametric
dependent data, the Wilcoxon test was applied. Multiple
measurements of normally distributed data were ana-
lyzed by the one-way repeated measurements ANOVA
or by the Kruskal-Wallis test in case of not normally
distributed data. Post hoc comparisons were performed
by Bonferroni’s multiple comparison test for normally
distributed data and by Dunn’s method for not normally
distributed data. Two-way repeated measurements
ANOVA was used for two factor analyses followed by
Bonferroni’s multiple comparison test. Statistical signifi-
cance was usually considered if P < 0.05. For the analysis
of repeated measurements, a Bonferroni correction was
performed in MS Excel to calculate t values with a step-
wise bisection of alpha starting with 0.05 according to
the equation t = TINV (alpha; degrees of freedom). The
residual degrees of freedom (DF), as calculated in the
test by GraphPad Prism V5, was used for these calcula-
tions. Then, t values obtained from the Bonferroni
multiple comparison tests were compared to the cor-
rected t values. If t(Bonferroni’s multiple comparison test) was
larger or equal to the corrected t value, the differences
were considered significant. Correlations of data were
performed using the Spearman correlation.
Results
Evaluation of chronic arthritis
Once the mice had reached the chronic phase of arthritis,
i.e., day 60 after induction, their joints were analyzed his-
tologically by hematoxylin and eosin (H&E) staining.
In addition to the comparison of ipsilateral (i.a. mBSA
induction) vs. contralateral (i.a. PBS) joints of the same
animals, we also examined a control group (induction-
only) that was not immunized s.c. but had only received
i.a. mBSA (tissue sections Fig. 1a–d). As expected, the
induction-only mice had significantly lower inflammation
scores when compared with ACIA mice (Fig. 1e, left panel).
The incidence of scores ≥4 was 100% in ACIA mice, but
less than 50% in induction-only mice. Higher scores (≥6)
were observed in 45% of the ACIA mice (N = 11) but only
in 11% of induction-only animals (N = 9).
Next, we compared ipsilateral with contralateral (i.a.
PBS) knee joints. The latter also developed inflammation
in later stages of the disease. Ipsilateral joints showed
higher severity scores than contralateral ones, but these
differences were not statistically significant.
Scores for joint destruction were highest for the
ipsilateral knees of ACIA mice (Fig. 1e, right panel).
Scores ≥4 were observed in 42% of the ACIA mice (N = 7)
but only in 14% of induction-only animals (N = 6).
Correlation of pain with parameters of inflammation
Throughout the acute and chronic phases of joint in-
flammation (Fig. 2), ACIA mice showed significantly
lower mechanical thresholds in the von Frey test in ipsi-
lateral (i.a. mBSA) compared to contralateral (i.a. PBS)
hind limbs (Fig. 2a). Animals that were not previously
immunized, but received only i.a. ipsilateral mBSA (in-
duction-only), showed a similar difference during the
acute phase of inflammation; however, this effect de-
creased as the inflammation subsided (Fig. 2a).
As shown in Fig. 2b, in ACIA mice, the ipsilateral paw
withdrawal latencies to heat were significantly lower
than the contralateral ones at all time points. In
induction-only animals, they were also significantly
lower during early joint inflammation, but not at later
time points (days 23–56).
The paw withdrawal latencies elicited by heat signifi-
cantly decreased with increasing severity and destruction
scores (Fig. 2c). In contrast, paw withdrawal thresholds
elicited by mechanical stimuli did not show a correlation
with parameters of inflammation or destruction (Fig. 2d).
In summary, the ACIA protocol induced hyperalgesia
and allodynia for at least 60 days after arthritis induction
and appears therefore suitable to study chronic pain
conditions in arthritis.
Opioid receptor antagonist exacerbates hyperalgesia
To investigate the role of endogenous opioids, we exam-
ined the effect of the opioid receptor antagonist NLXM.
This compound does not cross the blood brain barrier
[30] so that centrally mediated effects can be excluded.
ACIA and non-immunized mice received ipsilateral i.a.
NLXM in the chronic stage of arthritis (>day 60). Following
NLXM treatment, induction-only mice showed no differ-
ences in paw withdrawal latencies to mechanical stimula-
tion between ipsi- and contralateral sides, whereas paw
withdrawal latencies to heat were significantly reduced
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in ipsilateral limbs of ACIA mice as compared to
baseline thresholds (Fig. 3). Thus, endogenous opioids
seem to decrease heat hyperalgesia in the chronic
stage of our arthritis model.
CD8+ cells contribute to opioid action in chronic arthritis
The role of CD8+ T cells in chronic arthritis is con-
troversial [31, 32]. We depleted these cells 3 days
before i.a. injection of mBSA with a CD8-specific
antibody and repeated this treatment every 9 days.
Depletion efficacy was continuously surveyed by counting
CD8+ cells in the peripheral blood by flow cytometry
and was compared to mice receiving an isotype-
matched control antibody. Animals receiving the anti-
CD8 antibody displayed very low numbers of CD8+ T
cells in comparison to mice treated with the control
antibody at all time points (Fig. 4a). There were no
significant differences in baseline nociceptive thresh-
olds between CD8+-depleted and control animals
(Fig. 4b, c).
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Fig. 1 Histology of knee joint inflammation. H&E-stained knee joint sections of immmunized (a, b) and non-immunized (c, d) mice were analyzed
60–70 days after i.a. injection of mBSA (a, c) or PBS (b, d). Arrows indicate mononuclear cells infiltrating the synovial membrane and fibrosis, black
bar 250 μm. e (left panel), the magnitude of joint inflammation was determined in a 3 parameter scoring system for synovial hyperplasia (1–3 points),
infiltration of the synovial membrane by mononuclear cells (1–3 points), and fibrosis (1–3 points). e (right panel), the joint destruction
score was determined by adding up pannus formation (1–3 points) and cartilage and bone erosion (1–3 points). Statistical analysis
was performed using the Mann-Whitney U test to compare the scores between mBSA-injected knee joints of immunized (N = 11) and
non-immunized (N = 9) animals (*P < 0.05); the Wilcoxon signed rank test was used to compare the scores between mBSA- (ipsilateral)
and PBS-injected (contralateral) knee joints
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Both groups received i.a. NLXM either 16 or 60 days
after arthritis induction (Fig. 5a). At both time points,
arthritic mice treated with isotype-control antibody
showed significantly decreased thermal thresholds fol-
lowing NLXM injection, indicating exacerbated hyper-
algesia. In CD8+-depleted animals, however, NLXM had
no effect. These findings suggest an involvement of
CD8+ cells in the fine tuning of inflammatory pain by
the release of endogenous opioids at both stages. The
amount of Met-enkephalin released from joint cells of
CD8+-depleted animals was significantly lower than in
isotype control-treated animals (Fig. 5b left panel),
while cellular contents showed no statistically signifi-
cant differences (Fig. 5b right panel). The amount of
released beta-endorphin did not differ between the
treatment groups (Fig. 5c).
Impact of CD8+ cells on joint inflammation and
destruction
In accordance with our previous results, both control
antibody-treated as well as CD8+-depleted mice devel-
oped chronic arthritis in the later observation phases
(Fig. 6a, b). Mean scores of inflammation (Fig. 6a) or
destruction (Fig. 6b) did not differ statistically between
the groups. Also, serum levels of arthritis markers like
ACPA or antibodies against the inducing agent mBSA
were not different between CD8+-depleted and control
animals (Fig. 6c). However, serum levels of the pro-
inflammatory cytokines TNFα and IL-17 were signifi-
cantly increased in CD8+-depleted mice in the chronic
stages of the disease (Fig. 6d).
Discussion
The present study addressed an important link between
the nervous and immune systems in chronic inflam-
matory arthritis. Given that inflammation and opioids
modulate the sensitivity towards painful stimuli [18], we
examined arthritis-related mechanical and thermal noci-
ceptive responses as well as the effects of peripheral
opioid receptor blockade and lymphocyte depletion. Our
findings indicate that CD8+cells, usually considered
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Fig. 2 Mechanical allodynia and thermal hyperalgesia in ACIA and
control-treated mice. Paw withdrawal thresholds (a) and latencies (b)
were determined for both hind paws at the time points indicated
using von Frey filaments (a) and the Hargreaves test (b), respectively.
ACIA mice were immunized with s.c. mBSA and bovine collagen II,
and arthritis was induced by i.a. mBSA in the ipsilateral joint (open
squares), PBS was injected into the contralateral joint (black squares).
Control animals only received s.c. adjuvant and i.a. mBSA (open
circles) or PBS contralaterally (black circles). Data are represented as
means ± SEM. Statistical analysis was performed using the two-way
RM ANOVA and Bonferroni’s multiple comparison tests followed by
a Bonferroni correction comparing ACIA ipsi- vs. contralateral thresholds
(*P < 0.05, **P < 0.01, ***P < 0.001) and non-immunized ipsi- vs.
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harmful, may play a protective and analgesic role by
regulating pro-inflammatory cytokines and endogenous
opioid peptides in chronic stages of arthritis. In addition,
we found that the knee joints of ACIA mice >60 days
after onset of the disease displayed higher scores of in-
flammation as compared to induction-only animals that
had only received i.a. mBSA. Ongoing joint inflammation
in the ACIA model was accompanied by persistent mech-
anical allodynia and thermal hyperalgesia throughout the
entire observation period (i.e., 2 months) although
changes in thermal nociceptive thresholds were relatively
modest. Of note, while thermal nociceptive behaviours
correlated well with scores of inflammation, this was not
the case for mechanical nociceptive thresholds. Appar-
ently, more detailed measurements on mechanical noci-
ceptive behaviors (e.g., weight bearing, paw pressure) need
to be performed in future studies.
It is currently not clear if plastic changes in the noci-
ceptive system during acute inflammation are different
from those during chronic immune-mediated diseases
such as RA. Our goal was to identify possible thera-
peutic targets for chronic pain associated with RA.
Therefore, we needed to know whether ACIA could be
used to assess pain. Because pain parameters have not
been carefully studied in models of RA, we used two
different tests to measure mechanical (von Frey hairs)
and thermal hyperalgesia (Hargreaves test).
In induction-only animals, the nociceptive behaviors
observed after i.a. mBSA injection returned to control
levels (as determined in the PBS-injected contralateral
side) after 49 days with respect to mechanical allodynia,
and after 23 days for thermal hyperalgesia. Similar to
previous models of antigen-induced arthritis (AIA) in
mice [33], thermal hyperalgesia was strongest during the
first week after induction of ACIA. However, while AIA-
mice showed normal thermal thresholds after 21 days,
the thresholds remained lowered in ACIA until the end
of the observation period. In Lewis rats with AIA,
thermal thresholds remained reduced for 21 days [34].
Nociceptive thresholds in mice with collagen-induced
arthritis (CIA)-mice were studied using different tests
and can therefore not be directly compared with the
present findings. For example, knee pain was measured
in C57BL/6 mice with CIA as weight-bearing on the
hind limbs using an incapacitance meter [35] and devel-
oped later than in AIA and ACIA; it was detectable only
after approximately 15 days and then became constantly
stronger until the end of the observation period [35].
We found a strong correlation between thermal hyper-
algesia and scores of chronic inflammation and joint
destruction, indicating that the combination of AIA and
CIA results in a “pain” phenotype with a fast onset and
long duration, representing a novel and more appropri-
ate tool to investigate chronic pain.
The local injection of NLXM into the mBSA-treated
knee produced a short lasting but significant increase in
thermal hyperalgesia in ACIA but not in non-immunized
mice. This indicates the liberation of opioid peptides in
chronically inflamed tissue and extends our knowledge
gained from acute inflammatory models [24, 36, 37].
Importantly, no NLXM effect was detectable when the
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control antibody. a Success of CD8+ depletion was confirmed in the
peripheral blood by flow cytometry. Paw withdrawal thresholds and paw
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were determined during the onset of chronic ACIA at the time points
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and Hargreaves test (c), respectively. Data are represented as means ±
SEM. Statistical analysis was performed using the two-way RM ANOVA
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inflammation had resolved, as in non-immunized mice.
This supports the findings of several previous studies
demonstrating that immune cells can release opioid pep-
tides locally under inflammatory conditions [38]. In the
absence of such cells, no liberation of opioid peptides
seems to take place. Because mechanical thresholds were
too low to expect significant decreases after NLXM ad-
ministration, we did not test this. Again, more detailed
measurements on mechanical nociceptive behaviors (e.g.,
weight bearing, paw pressure) need to be performed in
future studies.
Our next question was to investigate the role of CD8+
cells in chronic ACIA with respect to joint destruction
and pain. Due to their cytotoxic capacity, CD8+ cells
(CTLs) contribute to tissue destruction in a variety of
physiologic and pathophysiologic processes. The damage
caused by these cells can be strong, as has been reported
for autoimmune diseases such as diabetes mellitus type
1, systemic lupus erythematosus, psoriasis vulgaris, and
multiple sclerosis [39]. This suggested that depletion of
CTLs might be beneficial in a disease model characterized
by inflammation, tissue destruction, and pain. In ACIA,
however, the majority of parameters investigated (auto-
antibody formation, chronic inflammation, and nocicep-
tive behaviours) did not improve after CD8-antibody
treatment, in accordance with previous studies [40, 41].
The histological evaluation of knee sections for signs
of chronic inflammation and destruction revealed no
significant differences between CD8+-depleted and non-
depleted ACIA-mice. This is in accordance with findings
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obtained in proteoglycan aggrecan-induced arthritis in
BALB/c mice [42]. Lower arthritis scores were observed
after CD8+ cell-depletion in mercuric chloride-induced
arthritis in rats [41]. However, mercuric chloride does
not lead to chronicity of the disease and these find-
ings cannot be directly compared to the situation in
chronic ACIA.
The role of CD8+ cells is controversial. Indeed, they
can also attenuate the clonal expansion of activated CD4
+ T cells [43, 44], secrete the anti-inflammatory cytokine
IL-10 [45, 46], or contribute to the downregulation of
Th17 cells [47]. In line with this notion, we found
increased levels of the pro-inflammatory cytokines TNFα
and IL-17 in the absence of CD8+ T cells in ACIA. The
blockade of IL-17 can lead to decreased joint inflamma-
tion and therefore, IL-17 is discussed as a potential
therapeutic target in RA [48]. In the K/BxN mouse
model, the development of spontaneous chronic arthritis
does not seem to be Th17-driven, as levels of IL-17 were
below detection limit in depleted and non-depleted
animals [40]. In contrast, the titer of IL-17 in ACIA
strongly suggests that such cells are present. This may
further explain the differences observed after CD8+
depletion comparing the two models. In CD8−/− mice,
the regulatory function of CD8+ cells became apparent
after re-challenge with the antigen followed by more se-
vere CIA compared to CD8+/− mice [49]; this resembles
our findings more closely.
In agreement with other arthritis models discussed
above [40–42, 49], no changes of the serologic auto-
antibody titers were detected after CD8+-depletion
in ACIA.
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The depletion performed in the present and in other
studies eliminated cytotoxic and regulatory CD8+ T cells
alike, a fact that could affect the experimental outcome
in several ways. The most pronounced consequences of
CD8+-depletion in several other arthritis models are
related to the deletion of their regulatory functions. The
K/BxN mouse model of spontaneous chronic arthritis
seems to be an exception and may represent a good
model to study the deleterious effects of CD8+ cells. It is
obvious that different arthritis models differ not only in
their experimental procedure (e.g., inducing agents, time
points of induction and cell depletion) but also in their
immune responses.
The basal nociceptive responses measured in ACIA,
mechanical allodynia, and thermal hyperalgesia, remained
unaffected by CD8+-depletion. To the best of our know-
ledge, there are no previous studies investigating nocicep-
tion after CD8+-depletion in chronic arthritis. In models
of acute inflammation, it was shown that endogenous
opioid-mediated analgesia depends on CD4+ T lympho-
cytes [18, 22]. In our study, CD8+-depleted ACIA animals
showed no decrease in their paw withdrawal latencies
after NLXM injection. This indicates an impaired opioid
system function in the absence of CD8+ cells. Additional
studies in order to evaluate the release from other cell
types are needed.
CD8+-depletion also leads to changes in the inflammatory
milieu in ACIA, e.g., the elevation of pro-inflammatory
cytokines, which could trigger the regulated release of Met-
enkephalin, in agreement with calcium-dependent opioid
peptide release induced by IL-1β and IL-6 [50]. Our data
indicate that CD8+-depletion might selectively affect Met-
enkephalin but not beta-endorphin liberation. These results
are in line with previous studies showing that CD4+ T
lymphocytes as well as CD8+ T lymphocytes produce
predominantly enkephalins in mice [22, 51]. Thus, the
selective reduction of enkephalin release may be explained
by the depletion of this predominant source of enkephalin.
Conclusions
In summary, using our chronic arthritis model, we could
demonstrate for the first time the development of chronic
pain and the correlation of joint inflammation and hyper-
algesia. Additionally, our data suggest a beneficial role
of CD8+ lymphocytes in endogenous opioid-mediated
analgesia.
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